Is GSK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

7,012 people get GSK articles and Market Currents by email alert.

Get email alerts on GSK »

HEADLINES:

The Billion Dollar COPD Deal: Who Gains The Most?
Emerging Equities • Fri, May 17 • 1 Comment
Complete Warren Buffett And Berkshire Hathaway 1st Quarter Portfolio Update
Profit Fan • Thu, May 16 • 9 Comments
Time To Show Optimism For Stocks
Bijoy Sinha • Thu, May 16 • 6 Comments
Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2013 Update
John Vincent • Thu, May 16 • 2 Comments
Amicus Therapeutics: The Good And The Bad
Biomed Group • Wed, May 15 • 2 Comments
3 Pharmaceuticals For Attractive Dividends
IAEResearch • Wed, May 15 • 5 Comments
Invest In Greece Because The Turnaround Has Already Started
Value Digger • Mon, May 13 • 15 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Mon, May 13 • 28 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
BREO™ ELLIPTA™ gains US approval for the treatment of COPD

PR Newswire (May 10, 2013)
Upcoming Catalysts Could Push ChemoCentryx To Double In 2013
BPD Research • Fri, May 10
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 59 Comments
Imminent Catalysts For Small Pharmaceuticals
Chemistfrog • Tue, May 7 • 9 Comments
Netupitant Results Could Roil Tesaro In May
Richard Pearson • Mon, May 6 • 9 Comments
Athersys Has Some Promise, But Controversy And Doubt Remain
Alberto Savrieno • Thu, May 2 • 25 Comments
Cramer's Mad Money - Pharmas Live Or Die By The Pipeline (5/1/13)
SA Editor Miriam Metzinger • Thu, May 2
3 Pharmaceutical Companies Awaiting FDA Approval, Part II
Emerging Equities • Tue, Apr 30
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Scott Matusow • Mon, Apr 29 • 10 Comments
Sarepta Therapeutics: Irrational Exuberance
George Rho • Thu, Apr 25 • 87 Comments
Will The Big Pharmaceuticals Fall Off A Patent Cliff?
Fund Gurus • Wed, Apr 24 • 2 Comments

High-Quality Glaxo Could Still Have Something Left
Stephen Simpson • Fri, Feb 8 • 10 Comments

GlaxoSmithKline: Not Making The Right Moves
StockRiters • Sun, Apr 14 • 9 Comments
GlaxoSmithKline's CEO On The Price Of New Drugs
Derek Lowe • Thu, Mar 21 • 2 Comments
GlaxoSmithKline - Against All Odds
StockRiters • Fri, Mar 1 • 4 Comments
GlaxoSmithKline Offers A High Dividend, But I Think It's Unsustainable
Jeroen Jongbloed • Wed, Feb 20 • 12 Comments
High-Quality Glaxo Could Still Have Something Left
Stephen Simpson • Fri, Feb 8 • 10 Comments
Glaxo's Genital Herpes Vaccine Flops But Genocea's Next-Generation Approach Makes It A Buy
Rex Graham • Sun, Dec 16, 2012 • 6 Comments
Discussing Amarin's Vascepa And GlaxoSmithKline's Lovaza With Omthera Pharma
Brian L. Wilson • Tue, Dec 4, 2012 • 67 Comments
Buy GlaxoSmithKline For 5.3% Dividend Yield, 10% Price Appreciation
Qineqt • Wed, Nov 28, 2012 • 2 Comments
GlaxoSmithKline Positioning For Clinical Trial Data Advantage
Alan Kotok • Mon, Nov 26, 2012
Buy GlaxoSmithKline If It Rises Above $45
QuandaryFX • Thu, Nov 22, 2012 • 3 Comments
4 Reasons To Buy This Top Pharma Stock For A Near 5% Yield
Hawkinvest • Mon, Nov 5, 2012 • 5 Comments
GlaxoSmithKline's Results Down - Dividends Up
Steven Dotsch • Thu, Nov 1, 2012 • 4 Comments
GlaxoSmithKline - A Few Reasons Not To Buy In Now
ValueMax • Tue, Oct 16, 2012 • 7 Comments
GlaxoSmithKline: Buy For 4.5% Yield
Cris Frangold • Mon, Oct 8, 2012 • 3 Comments
Was The HGSI Acquisition A Good Move For GlaxoSmithKline?
IncomeHunter • Tue, Aug 28, 2012 • 2 Comments
Pharmaceuticals And The Law: It's Not What You Think
Mel Daris • Mon, Aug 27, 2012 • 3 Comments
GlaxoSmithKline: Don't Pass On This Long-Term Gem
IncomeHunter • Tue, Aug 14, 2012 • 12 Comments
Using Options To Find Value In GlaxoSmithKline
Henry Stokman • Mon, Jul 30, 2012 • 1 Comment
GlaxoSmithKline's R&D Is Delivering, But The Street's Not Buying
Stephen Simpson • Wed, Jul 25, 2012 • 18 Comments
Glaxo And Human Genome Have Apparently Seen Reason
Stephen Simpson • Mon, Jul 16, 2012

The Billion Dollar COPD Deal: Who Gains The Most?
Emerging Equities • Fri, May 17 • 1 Comment
Complete Warren Buffett And Berkshire Hathaway 1st Quarter Portfolio Update
Profit Fan • Thu, May 16 • 9 Comments
Time To Show Optimism For Stocks
Bijoy Sinha • Thu, May 16 • 6 Comments
Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2013 Update
John Vincent • Thu, May 16 • 2 Comments
Amicus Therapeutics: The Good And The Bad
Biomed Group • Wed, May 15 • 2 Comments
3 Pharmaceuticals For Attractive Dividends
IAEResearch • Wed, May 15 • 5 Comments
Invest In Greece Because The Turnaround Has Already Started
Value Digger • Mon, May 13 • 15 Comments
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Mon, May 13 • 28 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Upcoming Catalysts Could Push ChemoCentryx To Double In 2013
BPD Research • Fri, May 10
Cellceutix Corporation: The Next Generation Of Cancer Treatment Has Arrived
The Progressive • Thu, May 9 • 59 Comments
Imminent Catalysts For Small Pharmaceuticals
Chemistfrog • Tue, May 7 • 9 Comments
Netupitant Results Could Roil Tesaro In May
Richard Pearson • Mon, May 6 • 9 Comments
Athersys Has Some Promise, But Controversy And Doubt Remain
Alberto Savrieno • Thu, May 2 • 25 Comments
Cramer's Mad Money - Pharmas Live Or Die By The Pipeline (5/1/13)
SA Editor Miriam Metzinger • Thu, May 2
3 Pharmaceutical Companies Awaiting FDA Approval, Part II
Emerging Equities • Tue, Apr 30
Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billion
Scott Matusow • Mon, Apr 29 • 10 Comments
Sarepta Therapeutics: Irrational Exuberance
George Rho • Thu, Apr 25 • 87 Comments
Will The Big Pharmaceuticals Fall Off A Patent Cliff?
Fund Gurus • Wed, Apr 24 • 2 Comments
Aveo's Inflection Point: Tivozanib Likely To Receive Positive Advisory Vote, FDA Approval
PropThink • Wed, Apr 24 • 37 Comments

GlaxoSmithKline's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, Apr 24
GlaxoSmithKline's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Feb 6
GlaxoSmithKline Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Oct 31, 2012
GlaxoSmithKline Management Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Jul 25, 2012
GlaxoSmithKline's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Wed, Apr 25, 2012
Human Genome Sciences' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Tue, Apr 24, 2012
Human Genome Sciences CEO Discusses Q4 2011 Results - Earnings Call Transcript
Mon, Feb 27, 2012
GlaxoSmithKline plc's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Feb 7, 2012 • 1 Comment
GlaxoSmithKline plc's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Wed, Oct 26, 2011
Human Genome Sciences CEO Discusses Q3 2011 Results - Earnings Call Transcript
Wed, Oct 26, 2011
GlaxoSmithKline plc's CEO Discusses Q2 2011 Results - Earnings Call Transcript
Tue, Jul 26, 2011
Human Genome Sciences' CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 22, 2011
GlaxoSmithKline plc's CEO Discusses Q1 2011 Results - Earnings Call Transcript
Tue, May 10, 2011
GlaxoSmithKline PLC (ADR) CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 3, 2011
Glaxosmithkline plc Q4 2009 Earnings Call Transcript
Thu, Feb 4, 2010
Human Genome Sciences Inc. Q1 2009 Earnings Call Transcript
Wed, Apr 29, 2009 • 1 Comment
Human Genome Sciences Inc Q4 2008 Earnings Call Transcript
Thu, Feb 26, 2009
Human Genome Sciences Inc. Q3 2008 Earnings Call Transcript
Thu, Nov 6, 2008
Human Genome Sciences Inc. Q2 2008 Earnings Call Transcript
Wed, Jul 30, 2008
Human Genome Sciences Inc. Q1 2008 Earnings Call Transcript
Mon, May 5, 2008

London Markets: GSK, Shell lead U.K. stocks to 8th day of gains

at MarketWatch.com (Mon, 12:07PM)
Europe Markets: Europe stocks retreat from 2013 high

at MarketWatch.com (Mon, 12:04PM)
BREO™ ELLIPTA™ gains US approval for the treatment of COPD

PR Newswire (May 10, 2013)
Futures Pare Gains After Durable Goods Orders

at CNBC.com (Apr 24, 2013)
Apple's Roller-Coaster Ride to Set Market Tone

at CNBC.com (Apr 23, 2013)
Big Pharma Exit: Who's Fighting the Superbugs?

at CNBC.com (Apr 23, 2013)
Europe Shares Close Higher on Mining Rebound

at CNBC.com (Apr 19, 2013)
London Markets: GSK, Vodafone rise in flat U.K. market

at MarketWatch.com (Apr 18, 2013)
Europe Markets: Spanish stocks rise in largely flat Europe market

at MarketWatch.com (Apr 18, 2013)
FDA Advisory Committee recommends approval of BREO™ ELLIPTA™ for the treatment of COPD

PR Newswire (Apr 17, 2013)
GlaxoSmithKline, Triangle Community Foundation Issue Call for Applications Totaling $400,000 in GSK IMPACT Awards

PR Newswire (Apr 17, 2013)
GlaxoSmithKline Issues Call for Applications Totaling $400,000 in GSK IMPACT Awards

PR Newswire (Apr 17, 2013)
London Markets: Miners rebound in London; pharma, oil firms off

at MarketWatch.com (Apr 16, 2013)
Europe Markets: Europe stocks extend losses to third day

at MarketWatch.com (Apr 16, 2013)
Midday Movers: ABX, KGC, IAU & More

at CNBC.com (Apr 15, 2013)
Cramer: Avoid This Drug Stock

at CNBC.com (Apr 11, 2013)
Cramer: Every Investor Needs a Stock Like This

at CNBC.com (Apr 10, 2013)
GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive Today

PR Newswire (Apr 6, 2013)
GlaxoSmithKline and Liberty Property Trust/Synterra Partners Transform the Work Environment with the Opening of Five Crescent Drive

PR Newswire (Apr 5, 2013)
Texas A&M System and GlaxoSmithKline receive U.S. Government approval to establish influenza vaccine facility in Texas

PR Newswire (Mar 26, 2013)

GSK vs. ETF Alternatives

Company Description

Human Genome Sciences, Inc. (“HGS” or the “Company”) is a commercially focused biopharmaceutical company advancing toward the market with three products in late-stage development: BENLYSTAtm for systemic lupus erythematosus (“SLE”), ZALBINtm for chronic hepatitis C, and raxibacumab for... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United Kingdom

All
| Earnings
| Dividends
| M&A
| On the move

Monday, May 13, 5:49 AM Elan (ELN) will make a one time cash payment of $1B to Theravance (THRX) for a 21% participation interest in future royalty payments from THRX's four respiratory collaborations with GlaxoSmithKline (GSK) including the recently-approved Breo Ellipta/Relvar treatment for COPD. The news comes on the heels of THRX's earnings report and concurrent announcement that it will split into two separate publicly traded companies. (PR) Comment! [Healthcare]
Friday, May 10, 12:09 PM GlaxoSmithKline (GSK +1.5%) and Theravance (THRX +11%) both move higher today after the FDA approves Breo Ellipta for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema. The approval was widely expected after a federal advisory panel endorsed the product last month. Comment! [Healthcare, On the Move]
Wednesday, May 8, 11:38 AM The 5% yield barrier on junk bonds (HYG, JNK) is broken for the first time ever, the Barclays U.S. High Yield Index sliding to 4.97% (prior to Jan., the yield had never fallen below 6%). Spreads to Treasurys remain at a not-unreasonable 406 bps, far wider than the record-tight 223 points reached just as the gates of financial heck were about to open in 2007. In the meantime, the equity of highly non-wobbly companies like RDS.A, VOD, and GSK yields in the area of 5%. "We don't want to question the market," writes the FT's David Keohane, "but: what the (heck)?" 7 Comments
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, April 29, 10:30 AM GlaxoSmithKline (GSK +0.1%) breaks off its relationship with Impax Laboratories (IPXL -1.1%) regarding the experimental Parkinson's drug Rytary due to "delays in the anticipated regulatory approval and launch dates in the countries in which GSK has rights to commercialize the product." GSK was working to develop and market Rytary outside of the U.S. and Taiwan. IPXL shares have yet to fully recover from a steep decline in March stemming from FDA concerns about the testing and evaluation process for Rytary. (PR) 1 Comment [Healthcare]
Friday, April 26, 12:19 PM GlaxoSmithKline (GSK +0.4%) says it's submitted a regulatory application in the European Union for umeclidinium bromide, or UMEC, an investigational once-daily medicine for patients with chronic obstructive pulmonary disease. Regulatory filings are pending in the U.S. and planned for other countries during the course of 2013. Comment! [Healthcare, Global & FX]
Thursday, April 18, 8:17 AM Theravance (THRX) looks poised for a strong session after an FDA advisory panel recommends approval of a once-daily COPD inhaled treatment option (Breo Ellipta) the company is developing with GlaxoSmithKline (GSK). Some color on the story: 1) the drug will be called "Relvar" in the U.S. 2) Annual sales should come in at ~$337M next year. 3) Treatment may be used in conjunction with GSK's $8B per year Advair. 4) Relvar will compete with AstraZeneca's Symbicort which had sales of $3.19B in 2012. THRX shares +16% premarket. 1 Comment [Healthcare, On the Move]
Wednesday, April 17, 2:39 PM An FDA advisory panel votes in favor of Theravance's (THRX) Breo Ellipta, saying the inhaler was safe and effective at treating COPD. The agency's pulmonary-allergy advisory committee is still reviewing the drug and has to vote on whether the product should be marketed, but today's positive vote makes it likely the panel will vote affirmatively to support approval. Shares remain halted. 1 Comment [Healthcare]
Wednesday, April 17, 10:47 AM Shares of Theravance (THRX) remain in limbo after being halted by Nasdaq earlier this morning, as the FDA meets today to discuss the company's new drug application for Breo Ellipta, a dry powder inhaler that treats chronic obstructive pulmonary disease. The drug is being sponsored by GlaxoSmithKline (GSK -0.9%). Comment! [Healthcare]
Tuesday, April 16, 2:05 PM Biogen Idec (BIIB +1.2%) and Roche's (RHHBY.PK) Genetech lose their appeal made in a patent infringement case against GlaxoSmithKline (GSK -0.1%). The Court upheld the interpretation of a BIIB patent covering the cancer drug Arzerra, ruling that GSK didn't infringe upon the patent. Comment! [Healthcare]
Tuesday, April 16, 9:03 AM A downgrade from Leerink Swann to Market Perform from Outperform adds to Sarepta Therapeutics' (SRPT) problems. The FDA's request has "prolonged uncertainty" and the need to run a Phase III trial preapproval could give GlaxoSmithKline (GSK) and Prosensa's drisapersen treatment a first-to-market advantage. SRPT shares now -10.17% premarket. 2 Comments [Healthcare, On the Move]
Monday, April 15, 11:12 AM Theravance (THRX +20.6%) tops the leader board as a staff report suggests Breo — a COPD treatment the company is developing with GlaxoSmithKline (GSK +3.1%) — could be set for approval by the FDA which will evaluate a recommendation Wednesday. There were some questions about side effects which Citi and UBS analysts said were expected. THRX will get royalties of 15% on the first $3B in sales and 5% thereafter. 1 Comment [Healthcare, On the Move]
Friday, April 12, 7:49 AM XenoPort (XNPT) says its restless leg drug Horizant is sold out, and in this case, that's a bad thing. GlaxoSmithKline (GSK), which has commercialization rights to the treatment through the end of this month, reports manufacturing delays have led to a stockout of Horizant. XNPT says it is "evaluating the impact, if any, this will have" on financial expectations. Shares -2.48% premarket. 1 Comment [Healthcare, On the Move]
Tuesday, April 2, 10:02 AM Optimer Pharmaceuticals (OPTR) surges 18.1% following a report that the antibiotics maker has attracted takeover interest from GlaxoSmithKline (GSK), AstraZeneca (AZN), Cubist Pharmaceuticals (CBST) and Japan's Astellas. Optimer hopes to fetch up to $1B in an auction, well above its market cap of $660M. The company has one drug on the market, Dificid, which is used to treat intestinal infections in hospitalized patients. 1 Comment [Healthcare, On the Move]
Thursday, March 28, 5:21 PM Bacteria that live in the gut change after gastric-bypass surgery and may aid in weight loss, according to a recent study. Gastric surgery helps people lose weight by shrinking the size of the stomach and making it tougher to absorb calories, now scientists think it may also adjust gastrointestinal bacteria, contributing to weight loss and raising the possibility for less-drastic obesity treatment. 7 Comments [Healthcare]
Monday, March 25, 10:26 AM GlaxoSmithKline (GSK -0.2%) says regulatory approval for its H5N1 bird flu vaccine has been delayed. The company blamed the setback on a "recently rectified administrative matter" and says it is working closely with the FDA to ensure the review will be wrapped up as soon as possible. Comment! [Healthcare]

Dividend Sheet
$GSK $AEP and $PFE are tomorrow's top ex-dividend stocks - http://stks.co/jUK4 - 2.7% average yield - $UL $PPG $WFC 49 ex-dividend stocks
May 7, 3:23 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Tony Kau
$GSK beautiful exhaustion, TE Score: -9 http://ow.ly/klBOi http://ow.ly/i/1XfP2
Apr 23, 1:40 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nathaniel Matherson
Buy This Stock On Relative Weakness: $MRK $LLY $GSK http://bit.ly/YRKc3U
Apr 16, 7:46 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chris Rees
Why Chris Rees expects the FDA to approve Aveo's Tivozanib $AVEO $PFE $GSK $$ http://bit.ly/ZpkNJz
Apr 11, 2:33 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$AZN $GSK $MRK are the best yielding heathcare stocks with a lower volatility than the market - http://stks.co/cP2U - $JNJ $TEVA
Apr 2, 5:32 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch: $IMSC.PK, $ANTB.OB, $FPMI.OB, $DIS, $MCD, $AZN, $TEV, $GSK, $KERX, $NVO, $AMRN - http://bit.ly/YJduvy
Mar 4, 7:16 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$PRK $GSK and $AVA are tomorrow's best yielding ex-dividend stocks - http://stks.co/bL7y - I like $MAT $DBD and $ROST - Average Yield: 2.8%
Feb 19, 8:10 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$GSK $HE and $CA are next week's best yielding ex-dividend stocks - http://stks.co/s2od - I like $MAT and $HSY - Average yield is 2.8%
Feb 16, 4:52 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ghosts of Kariela
Sold $ED and $GSK, opened a position in $SH, added to $SHLD, might buy some $UVXY,
Feb 14, 12:36 PM
Reply (2)

• !Report Abuse
View all 2 replies
NaveenB: You must be smelling a pull-back, SPY had a double-top.
Feb 14, 2:46 PM
• !Report Abuse
Ghosts of Kariela: No, I'm not smelling much of anything, but others are. The market rally is a bit overdone though.
Feb 14, 5:18 PM
• !Report Abuse
Add a reply...

140 characters

Ghosts of Kariela
Probably going to take profits on a lot of stocks tomorrow, probably $ED $GSK and perhaps trim $BAC a bit. Might buy $SH and more $SHLD.
Feb 14, 12:38 AM
Reply (3)

• !Report Abuse
View all 3 replies
NaveenB: I am thinking of selling covered calls on my SHLD position, if any thing, that will make the stock price rise...
Feb 14, 10:25 AM
• !Report Abuse
Ghosts of Kariela: Trimmed $BAC a bit for profits. Perhaps writing puts on $SHLD at this point?
Feb 15, 2:45 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Ghosts of Kariela
Probably going to take profits on a lot of stocks tomorrow, probably $ED $GSK and perhaps trim $BAC a bit. Might buy $SH and more $SHLD.
Feb 14, 12:38 AM
Reply (3)

• !Report Abuse
View all 3 replies
NaveenB: I am thinking of selling covered calls on my SHLD position, if any thing, that will make the stock price rise...
Feb 14, 10:25 AM
• !Report Abuse
Ghosts of Kariela: Trimmed $BAC a bit for profits. Perhaps writing puts on $SHLD at this point?
Feb 15, 2:45 PM
• !Report Abuse
Add a reply...

140 characters

Ghosts of Kariela
Sold $ED and $GSK, opened a position in $SH, added to $SHLD, might buy some $UVXY,
Feb 14, 12:36 PM
Reply (2)

• !Report Abuse
View all 2 replies
NaveenB: You must be smelling a pull-back, SPY had a double-top.
Feb 14, 2:46 PM
• !Report Abuse
Ghosts of Kariela: No, I'm not smelling much of anything, but others are. The market rally is a bit overdone though.
Feb 14, 5:18 PM
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
$BX $GSK and $TOT are the best yielding and most bought dividend stocks from investment gurus + http://stks.co/bKV1 + I like $INTC and $JNJ
Feb 11, 4:51 AM
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: I've been accumulating $BX.
Feb 12, 8:21 AM
• !Report Abuse
Add a reply...

140 characters

Dog of times
Buys: ING, AIG, PLX, OPTT, ELON, CHNG.PK, BWEN. Sales: GSK, XIDE, SLT. Sales, were trailing stop loss types with good gains. Buys are stopped.
12/5/09
Reply (1)

• !Report Abuse
View all 1 replies
117746: Tell me smething about ECHELON after sept 07,2007 until today has drop more than 90% why? today again funny play too low.
12/20/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
I am buying $FOLD, I think it has great shot to be a double from here. P3 Data soon for Fabry disease, $GSK owns 20% of CO. #AMICUS
10/4/12
Reply (2)

• !Report Abuse
View all 2 replies
IronmanVR4: Scott ATRS has moved as much as I thought it would..any reason?
10/4/12
• !Report Abuse
Scott Matusow: pinned near 4 for offering
10/4/12
• !Report Abuse
Add a reply...

140 characters

Shane Blackmon
$SGYP FV-100 looks interesting, 1 pill per day, rather than 12 pills with Valtrex. Valtrex had 339M pounds of sales in 2011 for $GSK.
8/23/12
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: What, are those pills made of lead or something?
8/23/12
• !Report Abuse
Shane Blackmon: ha, i dont have the symbol for British pounds on my computer... or else i just don't know how to do it.
8/23/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/ObIXDN New Upcoming FDA approval list for 2012 - 2013 $KIPS, $OMER, /4HEB, $BMTI, $PATH, $ONXX, $GSK, $POZN
7/19/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: AMRN
7/19/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
"GlaxoSmithKline (GSK) is nearing a deal to acquire Human Genome Sciences (GSK) for about $2.8 billion in cash." HGSI market cap is $2.7B.
7/16/12
Reply (1)

• !Report Abuse
View all 1 replies
Michael Bryant: http://yhoo.it/Nvk4pw
7/16/12
• !Report Abuse
Add a reply...

140 characters

Day Trader001
ARNA takeover target with GlaxoSmithKline (GSK) a logical suitor.
7/9/12
Reply (5)

• !Report Abuse
View all 5 replies
Day Trader001: Normally the ARNA would rise to offer price and the Purchaser slightly dips.
7/10/12
• !Report Abuse
candigolden: got it.
7/10/12
• !Report Abuse
Add a reply...

140 characters

Asif Suria
Human Genome $GSK Rejects $13/Share Bid from Glaxo $GSK; Calls It 'Inadequate' http://bit.ly/Kfmqrt
6/11/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: that has been ongoing...it has gotten very ugly
6/11/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://bit.ly/MkiyVr Premarket Gainer : $OCC $CTFO $FRAN $GSK $MOLX $FB $NBR
6/8/12
Reply (1)

• !Report Abuse
View all 1 replies
Maria Auziliadora: Yes FRAN!!!!
6/8/12
• !Report Abuse
Add a reply...

140 characters

nasdaqczar
GSK Downgraded to Avoid Target $10 Overpaying for GSK and a weak lupus drug eom
5/25/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: LOL who downgraded GSK to 10?? an 80% decline??
5/25/12
• !Report Abuse
iadops40: and avoid is not even a downgrade....is this your make believe terminology?
5/25/12
• !Report Abuse
Add a reply...

140 characters

The_American
GSK DNDN TNGN.OB CTIC STEM should ALL be looked at into the BIB space and PFE MRK GSK should be looking into much more MDT also looking AMRS X
4/21/12
Reply (6)

• !Report Abuse
View all 6 replies
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$ATRS I will be right about, just not today. Shorts still churning. they just want to be wrecked there lesson not learned from $GSK
4/27/12
Reply (4)

• !Report Abuse
View all 4 replies
gafigal: My IBIO c/b was 1.64, picked up more shares on dip, now at 1.63 and feel comfortable holding through 5/1 even if PLX PDUFA is negative.
4/27/12
• !Report Abuse
keiithc71: Scott forgive me if I am off here but are my calc correct in ATRS having low turnover ratio and high short %. Wouldnt this mean drop in pps?
5/14/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
Never going to learn you shorts on $ATRS; short more, then wake-up one day soon to see a bid that wipes you out. $GSK ring a bell?
4/26/12
Reply (11)

• !Report Abuse
View all 11 replies
Scott Matusow: SD Gafi imo is def working with short side trading groups. his article does not get the views they think. shorts already attacking before
4/26/12
• !Report Abuse
investlearner: Thank you Scott. I made a position in ATRS today around 3.06. Sitting tight
4/27/12
• !Report Abuse
Add a reply...

140 characters

GSK GlaxoSmithKline

GSK

GlaxoSmithKline